Welcome to the e-CCO Library!

P361: Machine learning models at week 6 of vedolizumab therapy for ulcerative colitis can predict week 52 corticosteroid free endoscopic remission
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Waljee A.1, Liu B.2, Sauder K.1, Zhu J.2, Govani S.1, Stidham R.W.1, Higgins P.D.*3

Created: Wednesday, 20 February 2019, 10:36 AM
P361: No increased postoperative risk of venous thromboembolism in patients with Ulcerative Colitis undergoing colectomy after tofacitinib exposure
Year: 2021
Source: ECCO'21 Virtual
Authors: De Greef, I.(1);Verstockt, B.(1);Bislenghi, G.(2);Terrasson, I.(2);Sabino, J.(1);Ferrante, M.(1);D’Hoore, A.(2);Vermeire, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P361: Patterns of use and durability of initial and sequential biological agents in a large Paediatric inflammatory bowel disease observational cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Kaplan1,2*, C. Liu3, E. King3, J. Bass4, A. Patel5, G. Tomer6, J. Tung7, J. Pratt3, S. Chen3, T. Lissoos8, R. Colletti9, ImproveCareNow Network

Created: Thursday, 21 February 2019, 9:14 AM
P361: PREPARE-IBD: Physician Responses to disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease during the COVID-19 pandemic: A multicentre cohort analysis
Year: 2022
Source: ECCO'22
Authors: Saifuddin, A.(1);Kent, A.(2);Mehta, S.(3);Hicks, L.(4);Gonzalez, H.(5);Segal, J.(4);Brooks, M.(6);Subramanian, S.(7);Bhala, N.(8);Conley, T.(7);Patel, K.(9);Lamb, C.(10);Walker, G.(11);Kennedy, N.(12);Sebastian, S.(5);
Created: Friday, 11 February 2022, 3:52 PM
P361: Risk of persistent gastrointestinal inflammation after treatment with immune checkpoint inhibitors
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jeay, M.(1)*;Carbonnel, F.(1);Robert, C.(2);Bellanger, C.(1);Meyer, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P362 Prospective study of phArmaCokinetics of InFliximab during induction in patients with Crohn’s disease and ulcerative colitis (PACIFIC)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Liefferinckx1, P. Bossuyt2, D. Thomas3, J.F. Rahier4, E. Louis5, F. Baert6, P. Dewint7,8, L. Pouillon2, G. Lambrecht9, S. Vermeire10, D. Franchimont1, of Belgian Inflammatory Bowel Disease Research and Development (BIRD)

Created: Thursday, 30 January 2020, 10:12 AM
P362: Anti-virus treatment against CMV in patients with ulcerative colitis by the PCR monitoring for mucosal CMV-DNA
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Tanaka*, T. Takagi, Y. Toyokawa, Y. Hotta, K. Uchiyama, Y. Naito, Y. Itoh

Created: Friday, 22 February 2019, 9:49 AM
P362: Faecal calprotectin is an early predictor of endoscopic response and histological remission after the start of vedolizumab
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. W. M. Pauwels*1, A. C. de Vries1, J. C. Goet1, N. S. Erler2, C. J. van der Woude1

Created: Friday, 22 February 2019, 9:41 AM
P362: Influence of HLA DQA1*05 genotype in patients with inflammatory bowel disease and Anti-TNF treatment with proactive therapeutic drug monitoring.
Year: 2022
Source: ECCO'22
Authors: Fuentes-Valenzuela, E.(1);García-Alonso , F.J.(1); Maroto-Martín , C.(1);Juan-Casamayor , L.(1);Garrote Adrados , J.A.(2);Almendros Muñoz , R.(3);de Prado , Á.(1);Marinero , M.Á.(1);Calleja Carbajosa , R.(1);Vara Castrodeza, A.(4);Barrio , J.(1);
Created: Friday, 11 February 2022, 3:52 PM
P362: Longitudinal antibody response to SARS-CoV-2 infection and antibody responses to COVID-19 vaccination in Inflammatory Bowel Disease patients receiving biologics
Year: 2021
Source: ECCO'21 Virtual
Authors: Wong, S.Y.(1);Dixon, R.(1);Gold, S.(1);Vicky, M.(1);Helmus, D.(1);Cadwell, K.(2);Colombel, J.F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P362: Magnetic resonance healing predicts long-term outcomes in patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Raimundo Fernandes S.*1, Correia L.1, Baldaia C.2, Moura Santos P.2, Rita Gonçalves A.2, Valente A.2, Velosa J.1

Created: Wednesday, 20 February 2019, 10:36 AM
P362: Six-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Cassieri1*, R. Pica1, E.V. Avallone1, G. Brandimarte2, M. Zippi1, P. Crispino1, D. De Nitto1, P.G. Lecca2, P. Vernia1, P. Paoluzi1, E.S. Corazziari1

Created: Thursday, 21 February 2019, 9:14 AM
P362: Systematic review: Oncological outcomes of patients with Inflammatory Bowel Disease undergoing segmental colonic resections for colorectal cancer and dysplasia
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Shamsiddinova, A.(1,2)*;Deputy, M.(1);Worley, G.(1);Rao, C.(2,3);Dean, H.(1);Thomas-Gibson, S.(4,5);Faiz, O.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P363 Moderate endurance and muscle training are safe to perform for patients with quiescent or mild active Crohn’s disease and increases their strength
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W.A. Seeger1,2, J. Thieringer1, P. Esters1, B. Allmendinger1, H. Schulze1, A. Dignass1

Created: Thursday, 30 January 2020, 10:12 AM
P363: Are clinical decision support tools for vedolizumab and ustekinumab in biologic naïve patients with Crohn’s disease drug-specific?
Year: 2022
Source: ECCO'22
Authors: Kim, J.E.(1);Won, H.(2);Kim, Y.H.(1);Kim, E.R.(1);Hong, S.N.(1);Chang, D.K.(1);
Created: Friday, 11 February 2022, 3:52 PM
P363: Depression and anxiety in Clostridioides difficile infection compared with inflammatory bowel disease during the Covid-19 pandemic
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Țurcan, S.(1)*;Platon, V.(1);Negru, I.(1);
Created: Friday, 14 July 2023, 11:05 AM
P363: Discontinuation of 5-aminosalicylates after starting biologic therapy in patients with ulcerative colitis is not associated with adverse outcomes
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Limketkai1*, R. Ungaro2, T. Jess3, K. Allin3, M. Agrawal4, T. Ullman2, J.-F. Colombel2

Created: Thursday, 21 February 2019, 9:14 AM
P363: Efficacy and safety of golimumab in patients with ulcerative colitis: a prospective multicentre study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

D. Varvara1, G. Costantino2, A.C. Privitera3, B. Principi4, M. Cappello5, S. Mazzuoli6, P. Paiano7, A. Tursi8, P. Paese9, W. Fries10, A. Andriulli1, F. Bossa*1

Created: Friday, 22 February 2019, 9:49 AM
P363: Locally injected allogeneic bone marrow-derived mesenchymal stromal cells for the treatment of refractory proctitis: clinical results of a phase IIa trial
Year: 2021
Source: ECCO'21 Virtual
Authors: OuboterDrs., L.(1,2);Barnhoorn, M.(1);van Pel, M.(2,3);Zwaginga, J.J.(4);Hawinkels, L.(1);Maljaars, J.(1);Koning, F.(2);Verspaget, H.(1);van der Meulen - de de Jong, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P363: The impact of transition to adult gastroenterology services on health-related quality of life in young adult patients with IBD: the UK TRANSIT study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

McCartney S.*1, Lindsay J.2, Russell R.3, Gaya D.3, Shaw I.4, Murray C.5, Finney-Hayward T.6, Sebastian S.7

Created: Wednesday, 20 February 2019, 10:36 AM